Skip to main content

Day: January 4, 2023

Cingulate Initiates Phase 3 Study of Lead Asset CTx-1301, Designed as a True Entire Active-Day Treatment for ADHD

Trial Results Expected 1H 2023 Company to Host Investor and Business Development Meetings Adjacent to Upcoming J.P. Morgan Healthcare Conference in San Francisco KANSAS CITY, Kan., Jan. 04, 2023 (GLOBE NEWSWIRE) — Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced the initiation of the first Phase 3 clinical trial of its lead candidate CTx-1301, a novel, investigational, trimodal, extended release tablet formulation of dexmethylphenidate, a compound approved by the U.S. Food and Drug Administration (FDA) for the treatment of attention deficit/hyperactivity disorder (ADHD). Along with the commencement of its Phase 3 trial, the...

Continue reading

TELUS International completes acquisition of WillowTree, a full-service digital product provider

Premium front-end design and development competencies open joint cross-selling opportunities across a more highly diversified client base Robust profitable growth and cash flow profile of both companies supports continued rapid deleveraging VANCOUVER, British Columbia, Jan. 04, 2023 (GLOBE NEWSWIRE) — Today, TELUS Corporation (T-TSX; NYSE-TU) and TELUS International (NYSE and TSX: TIXT), a leading digital customer experience innovator that designs, builds and delivers next-generation solutions, including AI and content moderation, for global and disruptive brands, announced the completion of the previously announced acquisition of WillowTree, having met all closing conditions and regulatory approvals. Now rebranded as WillowTree, a TELUS International Company, the premier, full-service digital product provider adds key front-end...

Continue reading

UTStarcom Announces New SyncRing PTP Grandmaster

HANGZHOU, China, Jan. 04, 2023 (GLOBE NEWSWIRE) — UTStarcom (“UTStarcom” or “the Company”) (NASDAQ:UTSI), a global telecommunications infrastructure provider, today introduced the SyncRing XGM30E PTP grandmaster, a new addition to its SyncRing family of network synchronization equipment. UTStarcom’s SyncRing time synchronization solution is designed for use in mobile networks and other applications where accurate time and frequency synchronization is a critical requirement. Using a distributed clustered timing architecture, the SyncRing solution enables instant implementation of accurate time and frequency delivery regardless of existing network capabilities. This solution’s architecture uses multiple timing sources (“Grand Masters”) deployed closer to the edge of the network, within minimum number of hops from end applications,...

Continue reading

Reviva Pharmaceuticals Announces Letter to Shareholders

CUPERTINO, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), cardiovascular, metabolic, and inflammatory diseases, is pleased to announce a letter to shareholders from Founder, President, and CEO, Laxminarayan Bhat, Ph.D. The full text of the letter follows. Dear Fellow Shareholders: It is with great pride and enthusiasm that I write this shareholder letter to you today. Despite COVID-19 and shifting geopolitical landscape resulting in widespread delays that have impacted a large number of clinical trials in recent years, Reviva Pharmaceuticals remains on track to report top-line data in mid-2023 from our global,...

Continue reading

Eagle Bancorp Announces Earnings Call On January 19, 2023

BETHESDA, Md., Jan. 04, 2023 (GLOBE NEWSWIRE) — Eagle Bancorp, Inc., (the “Company”) (NASDAQ: EGBN), the parent company of EagleBank, today announced that it will host a teleconference call for the financial community on January 19, 2023 at 10:00 a.m. (EST) to discuss its fourth quarter and year end 2022 financial results. Those results will be released after the close of business on January 18, 2023. Interested parties will need to register at the below-noted URL in order to listen and participate in the call. Once a participant registers with a valid email, they will receive a dial-in phone number and unique PIN number which will be needed to access the call.   The call will also be available live via webcast on the Company’s website, which is www.EagleBankCorp.com. A replay of the call will be available on the Company’s website...

Continue reading

Coherent to Present at the 25th Annual Needham Growth Conference

PITTSBURGH, Jan. 04, 2023 (GLOBE NEWSWIRE) — Coherent Corp. (Nasdaq: COHR), a global leader in materials, networking, and lasers, announced today that the company will present at the following upcoming investor conference:25th Annual Needham Growth ConferenceDate:     Thursday, Jan. 12, 2023Time:   10:15 a.m. ET     ParticipantMary Jane Raymond, Chief Financial Officer     A real-time audio webcast of the presentation can be accessed via the Investor Relations section of the Coherent website at https://www.coherent.com/company/investor-relations/financial-webcasts. A replay of the webcast will be available on the company’s website following the conclusion of the event. About Coherent Coherent empowers market innovators to define the future through breakthrough technologies, from materials to systems. We deliver...

Continue reading

Radware Schedules Conference Call for Its Fourth Quarter and Full Year 2022 Earnings

TEL AVIV, Israel, Jan. 04, 2023 (GLOBE NEWSWIRE) — Radware® (NASDAQ: RDWR), a leading provider of cyber security and application delivery solutions, will announce its fourth quarter and full year 2022 financial results on Wednesday, February 8, 2023. Conference Call DetailsRadware management will host a call on Wednesday, February 8, 2023, at 8:30 a.m. EST to discuss its fourth quarter and full year 2022 results and outlook for the first quarter of 2023. Participants are advised to join the call approximately 15 minutes before the start time. US: 1-888-510-2008 (toll free) International: 1-646-960-0306Conference ID: 1864701 In addition, the call will be webcast live on the Company’s website at http://www.radware.com/ir/investor-events/. A replay of the call will be available for two days, starting two hours after the end...

Continue reading

Applied Therapeutics Announces Partnership with Advanz Pharma for Commercialization of AT-007 (Govorestat) in Europe

Advanz Pharma will leverage its specialty, hospital, and rare disease expertise and infrastructure to commercialize AT-007 in Europe for both Galactosemia and SORD Deficiency Applied Therapeutics will receive milestone payments of over €130 million and 20% royalty payments on net sales in Europe Deal strengthens Applied Therapeutics’ capital position and extends cash runway through key milestonesNEW YORK, Jan. 04, 2023 (GLOBE NEWSWIRE) — Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced a partnership with Advanz Pharma, a pharmaceutical company with a strategic focus on commercialization of specialty, hospital, and rare disease medicines, for commercialization...

Continue reading

Ultragenyx to Present at the 41st Annual J.P. Morgan Healthcare Conference

NOVATO, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) — Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the company’s chief executive officer and president, will present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023, at 12:45 PM ET. The live and archived webcast of the presentation will be accessible from the company’s website at https://ir.ultragenyx.com/events-presentations. The replay of the webcast will be available for 30 days. About Ultragenyx Pharmaceutical Inc. Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultra-rare...

Continue reading

Roivant Announces Statistically Significant and Clinically Meaningful Results from the Induction Period of TUSCANY-2, a Large Global Phase 2b Study of Subcutaneous RVT-3101 for the Treatment of Ulcerative Colitis in Both the Overall and the Biomarker Positive Patient Populations

RVT-3101 demonstrated statistically significant and clinically meaningful efficacy at each dose tested Across all patients treated with RVT-3101, the clinical remission and endoscopic improvement rates were 32% and 40%, respectively. Similar results were observed at the expected Phase 3 dose At the expected Phase 3 dose, among patients who were positive for a biomarker that was prospectively defined in TUSCANY-2, clinical remission and endoscopic improvement rates were 40% and 56%, respectively. Approximately 60% of patients were identified as positive for this biomarker At the expected Phase 3 dose, among patients who had been previously treated with biologics and who were biomarker positive, clinical remission and endoscopic improvement rates were 41% and 56%, respectively Across all doses and patient groups, RVT-3101 was well tolerated...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.